ProCE Banner Activity

Sequencing BTK Inhibitors in Treatment of Marginal Zone Lymphomas

Clinical Thought
Now that ibrutinib and zanubrutinib are both approved by the FDA in the relapsed/refractory setting for marginal zone lymphoma, where do we sequence and how do we choose between these BTK inhibitors? Read this commentary for my approach.

Released: November 02, 2021

Expiration: November 01, 2022

Share

Faculty

John P. Leonard

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Atara Biotherapeutics

Bayer Healthcare Pharma

BeiGene, Ltd.

Epizyme

Genentech, a member of the Roche Group

Genmab US, Inc.

Incyte Corporation

Karyopharm Therapeutics

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Faculty Disclosure

Primary Author

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

John P. Leonard, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Epizyme, Genentech/Roche, GenMab, Gilead Sciences/Kite, Incyte, Janssen, Karyopharm, MEI Pharma, Miltenyi, Regeneron, and Sutro and funds for research support from Genentech and Janssen.